BIOVAXYS ANNOUNCES SHARE CONSOLIDATION
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 05 2025
0mins
Source: PRnewswire
Share Consolidation Announcement: BioVaxys Technology Corp. is consolidating its common shares at a ratio of 10 pre-consolidation shares for 1 post-consolidation share, effective September 11, 2025, pending approval from the Canadian Securities Exchange (CSE).
Impact on Shareholders: Following the consolidation, the number of outstanding shares will decrease from approximately 293 million to about 29 million, with adjustments made for any fractional shares, and registered shareholders will receive a letter of transmittal for the exchange of physical certificates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
